PMID- 29369007
OWN - NLM
STAT- MEDLINE
DCOM- 20180813
LR  - 20211204
IS  - 1532-4281 (Electronic)
IS  - 1079-9893 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Feb
TI  - Combination therapy Eve and Pac to induce apoptosis in cervical cancer cells by 
      targeting PI3K/AKT/mTOR pathways.
PG  - 83-88
LID - 10.1080/10799893.2018.1426610 [doi]
AB  - This study aimed to investigate the anti-cervical cancer effects of everolimus 
      (Eve) and paclitaxel (Pac) when used alone or in combination. Human cervical 
      cancer cells HeLa and SiHa were divided into four group: Blank control group 
      (control), everolimus group (Eve), paclitaxel group (Pac) and combined therapy 
      group (Eve + Pac). The cell viability was detected by CCK-8 assay and the cell 
      cloning ability was detected by clonegenic assay. Flow cytometry was used to 
      detect cell apoptosis. Meanwhile, the expression of phosphatidylinositol 3-kinase 
      (PI3K), protein kinase B (AKT), mammalian target of rapamycin (mTOR) and their 
      phosphorylated proteins were studied by western blot. The HeLa and SiHa cells 
      proliferation and cloning ability were significantly inhibited in drug treatment 
      groups compared with control group (p < .05), and the Eve + Pac combinatorial 
      therapy showed the better results than single treatment with Eve or Pac. 
      Combination of Eve and Pac has synergistic effect on the induction of apoptosis 
      in cervical cancer cells. In addition, the protein ratios in HeLa and SiHa cell 
      treated with the Eve + Pac combination were significantly lower than that of 
      cervical cancer cells treated with either Eve or Pac cell alone. Our study 
      suggested that Eve + Pac provide a novel therapeutic strategy for cervical 
      cancer.
FAU - Dong, Pingping
AU  - Dong P
AD  - a Department of Obstetrics , Yantaishan Hospital , Yantai , China.
FAU - Hao, Fengmei
AU  - Hao F
AD  - b Department of Gynaecology and Obstetrics , Qingdao 3rd People's Hospital , 
      Qingdao , China.
FAU - Dai, Shufeng
AU  - Dai S
AD  - c Department of Gynecology , Qingdao 3rd People's Hospital , Qingdao , China.
FAU - Tian, Lin
AU  - Tian L
AD  - b Department of Gynaecology and Obstetrics , Qingdao 3rd People's Hospital , 
      Qingdao , China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Recept Signal Transduct Res
JT  - Journal of receptor and signal transduction research
JID - 9509432
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Antineoplastic Agents
MH  - Apoptosis/drug effects
MH  - Cell Proliferation/*drug effects
MH  - Clonal Evolution/drug effects
MH  - Drug Screening Assays, Antitumor
MH  - Drug Synergism
MH  - Everolimus/*administration & dosage
MH  - Female
MH  - HeLa Cells
MH  - Humans
MH  - Paclitaxel/*administration & dosage
MH  - Phosphatidylinositol 3-Kinases/genetics
MH  - Proto-Oncogene Proteins c-akt/genetics
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/genetics
MH  - Uterine Cervical Neoplasms/*drug therapy/genetics/pathology
OTO - NOTNLM
OT  - Everolimus (Eve)
OT  - PI3K/AKT/mTOR pathway
OT  - apoptosis
OT  - cervical cancer cells
OT  - paclitaxel (Pac)
EDAT- 2018/01/26 06:00
MHDA- 2018/08/14 06:00
CRDT- 2018/01/26 06:00
PHST- 2018/01/26 06:00 [entrez]
PHST- 2018/01/26 06:00 [pubmed]
PHST- 2018/08/14 06:00 [medline]
AID - 10.1080/10799893.2018.1426610 [doi]
PST - ppublish
SO  - J Recept Signal Transduct Res. 2018 Feb;38(1):83-88. doi: 
      10.1080/10799893.2018.1426610.